Active Energy financial advisor Adrian Rowles on digital asset strategy

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive's Stephen Gunnion about the company’s landmark offtake agreement for its Villeta Project in Paraguay. The project is described by Mussat as the first industrial-scale, fully dedicated green fertiliser facility. Powered by renewable energy, it will convert green hydrogen into ammonia and ultimately produce 260,000 tons per year of calcium ammonium nitrate fertiliser. Mussat explained, “Offtake means who is going to buy your product, at what price, and for how long? Because that determines the bankability of your project.” He confirmed that ATOME has signed a ten-year take-or-pay agreement with Yara, one of the world’s largest fertiliser companies, covering 100% of production, with an option to renew. He highlighted that Yara sells over 6 million tons of fertiliser annually in Latin America, making it a significant long-term partner. The CEO emphasised that this partnership ensures guaranteed revenues before construction even begins, which is a critical factor in securing financing. He noted that ATOME has already purchased land, completed environmental and social impact assessments, and agreed on EPC terms with Casale. The next steps will focus on finalising financing with equity led by Hy24 and debt discussions involving institutions such as IDB, FMO, the European Investment Bank, and IFC. Visit Proactive’s YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe, and enable notifications so you never miss future content. #ATOME #GreenFertilizer #VilletaProject #Yara #RenewableEnergy #GreenHydrogen #Ammonia #SustainableAgriculture #ProjectFinance #ProactiveInvestors

Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF) treasury advisor Adrian Rowles talked with Proactive's Stephen Gunnion about the company’s newly outlined digital treasury strategy and its role in supporting renewable energy operations. Rowles explained that the approach is “compliance-led and diversified, building resilience and scaling carefully,” with a clear 12 to 24-month roadmap. In the first year, the focus will be on structure and transparency, while by the second year, digital assets are expected to deliver a meaningful contribution to operational income. A portion of the company’s recent £2.50 million capital raise has been earmarked for treasury management, with around 30% of working capital to be placed into digital assets. Rowles noted that reserves will be primarily held in Bitcoin and Ethereum, but there are also plans to explore alternative opportunities, such as hedging strategies to better manage crypto cycles and generate a predictable yield. He emphasised that success will be measured through safety, liquidity, and risk-adjusted returns. Assets will be held with regulated partners, diversification caps will limit exposure to any single asset, and safeguards will be tested to ensure cautious but efficient management. Rowles highlighted that the integration of digital assets with renewables is designed to create sustainable income streams that strengthen the group’s core operations. For more updates from Proactive, visit our YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications so you never miss future content. #ActiveEnergyGroup #DigitalTreasury #CryptoStrategy #Bitcoin #Ethereum #RenewableEnergy #TreasuryManagement #DigitalAssets #SustainableFinance #CryptoTreasury

International Lithium Corp. (TSX-V:ILC, OTCQB:ILHMF) chairman and CEO John Wisbey talked with Proactive's Stephen Gunnion about the company’s latest strategic developments, including its option to acquire Lepidico’s interest in the Karibib Lithium, Rubidium and Cesium project in Namibia. Wisbey explained that the Karibib project brings both scale and advanced development, with a feasibility study already completed in 2020. He highlighted that the resource contains significant lithium, a substantial rubidium component, and enough cesium to meet a year of global demand. “Our research shows, that was validated by some external research, shows that it's the largest declared rubidium resource in Africa,” he noted. He described the project as complementary to International Lithium’s Raleigh Lake project in Canada, which has already reached the PEA stage and also contains both lithium and rubidium. Namibia’s proximity to Zimbabwe, where the company has pending applications, was also seen as a geographic advantage. If the option is exercised, Wisbey said the immediate focus will be on due diligence, establishing a drilling program to expand resources, and aligning reporting with Canadian NI 43-101 standards. He added that financing will be supported by proceeds from past asset sales, with further planning under discussion with investors. The company emphasized that there is a possibility that the option may not be exercised, especially if Lepidico Namibia encounters an adverse outcome in an arbitration dispute with the Chinese company Jiangxi Jinhui Lithium Co. Ltd., which involves claims and counterclaims. This arbitration in Singapore is expected to conclude in September or October 2025. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Lithium #Rubidium #CriticalMetals #InternationalLithium #Mining #Namibia #BatteryMetals #EnergyTransition #RaleighLake #ProactiveInvestors

Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share that the company presented four scientific posters at the PAINWEEK 2025 conference in Las Vegas, Nevada, showcasing robust data from two pivotal Phase 3 trials of Tonmya® for the treatment of fibromyalgia. The first study, RELIEF, was a 14-week randomized, double-blind, placebo-controlled trial, while the second, RESILIENT, served as a confirmatory efficacy and safety trial. Results across both studies demonstrated that Tonmya significantly reduced fibromyalgia-related pain while maintaining a favorable tolerability profile. Unlike conventional pain therapies, Tonmya is designed to pharmacologically target nonrestorative sleep by antagonizing receptors that regulate sleep architecture—addressing a central mechanism thought to perpetuate fibromyalgia symptoms. Dr. Lederman noted that beyond reducing pain, Tonmya’s mechanism of action may help improve a wide spectrum of fibromyalgia symptoms, potentially supporting earlier diagnosis, timely intervention, and improved long-term outcomes. Importantly, the therapy represents a non-opioid treatment option at a time when safer alternatives are in high demand. With FDA approval secured, Tonix is now preparing to launch Tonmya commercially in the coming quarter, marking a transformative milestone for both the company and the fibromyalgia community. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #Tonmya #Fibromyalgia #FDAApproval #NonOpioid #PainManagement #ChronicPain #NociplasticPain #Cyclobenzaprine #MoveFibroForward #Painweek2025

Arrow Exploration CEO Marshall Abbott joined Steve Darling from Proactive to provide a comprehensive operational update on the company’s rapidly advancing activities in Colombia. Abbott revealed that Arrow has successfully made three new oil discoveries in the region—discoveries that have already led to the drilling of 39 development wells. He described this as evidence of the project’s “scope and repeatability,” underscoring the company’s ability to consistently replicate exploration success and swiftly convert it into production. Abbott noted that Arrow has emerged as one of the most active and dynamic operators in Colombia’s oil sector. The company is currently producing approximately 4,800 barrels of oil per day, representing a 45% increase compared to the same period last year. This surge in production highlights the effectiveness of Arrow’s drilling program and its ability to rapidly scale output from newly discovered resources. Looking ahead, Abbott said the company will continue to pursue a strategy focused on low-risk exploration drilling to drive further growth. One exploration well is scheduled to spud on September 16, with three additional wells planned to follow shortly thereafter. He emphasized that this steady pipeline of drilling activity is designed to unlock new reserves while maintaining predictable operational performance. Abbott also discussed the company’s investments in critical water disposal infrastructure—a key component in supporting sustained production growth. “Now we have the capacity to handle just under 140,000 barrels of water per day with three disposal wells,” he explained. This expanded capacity allows Arrow to increase pump speeds across its producing wells, which in turn supports higher production rates and operational efficiency. Financially, Arrow remains in a robust position. The company is currently debt free and holds approximately $13 million in cash, with strong monthly cash flow supporting both ongoing operations and growth initiatives. Abbott confirmed that Arrow has set an internal target of reaching 10,000 barrels per day, a goal the company plans to achieve through a combination of organic growth from its existing portfolio and strategic asset acquisitions that complement its core operations in Colombia. #proactiveinvestors #arrowexplorationinc #aim #axl #tsxv #axl #ColombiaEnergy #MarshallAbbott #Q1Results #OilDrilling #EnergyInvestment #SeismicSurvey #WaterDisposal #PrepaymentDeal #ExplorationAndProduction #LlanosBasin #EnergySector #ProactiveInvestors

Sigyn Therapeutics, Inc. has announced plans to initiate a multi-site clinical feasibility study evaluating its breakthrough Sigyn Therapy™ in patients with high-risk cardiovascular disease, the world’s leading cause of death, according to the World Health Organization. CEO Jim Joyce told Proactive that Sigyn Therapy is a first-in-class whole-blood adsorption technology designed to be deployed on existing dialysis machines already found in hospitals and clinics worldwide. Unlike conventional approaches, the therapy is engineered to address multiple drivers of cardiovascular disease progression in a single treatment. Specific to CVD, Sigyn Therapy has been shown to reduce circulating inflammatory molecules that accelerate disease progression, while simultaneously targeting cholesterol-transporting lipoproteins that are responsible for heart attacks, strokes, and other major adverse cardiovascular events. Building on encouraging results from pre-clinical in vitro studies, the company is expanding its feasibility study protocol to include the measurement of lipoprotein reduction during therapy. This will allow investigators to quantify the dual-action benefit of Sigyn Therapy in reducing both inflammation and lipid-related risks. The upcoming feasibility study will be a critical step toward the company’s long-term goal: advancing to a pivotal efficacy study required for potential regulatory clearance and commercialization. If successful, Sigyn Therapy could represent a transformative advancement in the treatment of cardiovascular disease by integrating seamlessly into existing hospital infrastructure while addressing some of the most urgent unmet needs in cardiac care. Joyce added that the company is in the process of modifying its Investigational Device Exemption (IDE) for submission to the FDA, to formally include Ldl-c and Lp(a) reduction as observational endpoints. #proactiveinvestors #sigyntherapeuticsinc #otcqb #sigy #CardiovascularDisease #Dialysis #SigynTherapeutics #MedicalDevices #BloodPurification #ClinicalTrials #Lipoproteins #StatinAlternative #EndStageRenalDisease #FDAReview

Happy Creek Minerals CEO Jason Bahnsen joined Steve Darling from Proactive to announce the commencement of a large-scale diamond drilling campaign at the company’s 100%-owned Fox Tungsten Project, located in the South Cariboo district of British Columbia. This new 2025/2026 exploration program marks an important step toward growing the project’s already impressive high-grade resource base and advancing it toward development as a key supplier of critical minerals in North America. Bahnsen explained that the company has planned up to 100 diamond drill holes totaling approximately 10,000 metres as part of this resource expansion initiative. The campaign will target several newly identified zones that were outlined through geological mapping, prospecting, and follow-up work from earlier drill programs. By systematically testing these zones, the company aims to significantly increase the size and confidence level of the existing NI 43-101 resource estimate. The Fox Tungsten Project is considered one of the highest-grade tungsten deposits globally, positioning it as a strategic domestic source of this critical metal, which is essential for applications ranging from defense systems to renewable energy and advanced manufacturing. Happy Creek’s most recent NI 43-101 estimate from 2018 outlined 582,400 tonnes at 0.83% tungsten trioxide (WO₃) in the Indicated category and 565,400 tonnes at 1.23% WO₃ in the Inferred category. Bahnsen noted that expanding the resource will strengthen the project’s potential to play a key role in supplying secure, local tungsten to the North American critical metals market, reducing reliance on foreign supply chains. #proactiveinvestors #happycreekmineralsltd #tsxv #hpy #Tungsten #HappyCreekMinerals #FoxProject #CriticalMinerals #ResourceExpansion #DrillingUpdate #MiningNews #CanadianMining #StrategicMetals #DefenseMetals

VettaFi Head of Energy Research Stacey Morris joined Steve Darling from Proactive to share her insights on the outlook for the midstream energy sector as 2025 nears its end. Morris began by defining midstream companies as the “logistics arms of the energy space,” explaining that they are primarily responsible for transporting, storing, and processing energy commodities such as oil, natural gas, and natural gas liquids. She emphasized that midstream operators are typically structured around a fee-based business model, which allows them to generate stable and predictable cash flows regardless of commodity price volatility. Morris highlighted that free cash flow generation remains a cornerstone strength across the midstream sector. This consistent financial performance has enabled companies to return significant capital to shareholders through dividend growth and share buyback programs, reinforcing investor confidence. “The free cash flow theme is very much still intact for this space,” she noted, underscoring the resilience of the sector even amid shifting market dynamics. A major growth catalyst for midstream companies, Morris said, is the rapidly increasing global demand for natural gas. She pointed out that U.S. liquefied natural gas (LNG) export capacity is expected to expand by 80% by 2030, driven by large-scale projects that are already under construction. This export boom is being complemented by rising electricity demand within the U.S., much of which is anticipated to be powered by natural gas—a trend that could further bolster throughput volumes and revenue opportunities for midstream firms. Morris also cited a more favourable U.S. regulatory environment under the current administration as a supportive factor, noting that policymakers appear more receptive to new pipeline construction and LNG infrastructure expansion. This regulatory backdrop is helping reduce permitting hurdles and enabling companies to advance long-term capital projects that can drive growth. For European investors seeking to gain exposure to this resilient part of the energy market, Morris highlighted the American Midstream Energy Dividend UCITS ETF as a potential vehicle. She said the ETF can serve multiple purposes within a portfolio, including providing consistent income through dividends, offering defensive exposure to the energy sector, and delivering diversification benefits compared to traditional European energy majors such as Shell and BP. #proactiveinvestors #MidstreamEnergy #EnergyETF #NaturalGasDemand #StaceyMorris #EnergyInfrastructure #AlerianETF #OilPrices #LNG #InvestorInsights #CommodityMarkets #EnergyMarketUpdate #DefensiveInvesting #ProactiveInvestors

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier takes Proactive's Stephen Gunnion through the company’s annual results and latest business update. He highlighted progress across Scancell’s clinical pipeline, particularly the SCOPE study in melanoma. L’Huillier said the trial has answered four critical questions, including product selection, target patient population, administration, and dosing schedule. The company has chosen its iSCIB1+ candidate for further development, after observing “meaningful clinical benefit comes from administering our drug on top of standard of care.” He noted that the therapy is showing strong results in patients with specific HLA haplotypes, with the ability to use a screening tool to identify responders for future trials. On efficacy, L’Huillier explained: “In our combined cohort, in the target population where we've got 72 patients, we're seeing a progression-free survival of 69% at 22 months. And if you compare that to the historic standard of care, it's 11.5 months.” The CEO also discussed the Modi-1 programme in phase 2 for head and neck cancer and renal cell carcinoma, and progress on antiglycan antibodies, which are being advanced under a new subsidiary. Looking ahead, Scancell is preparing for regulatory discussions with the FDA, EMA and MHRA, while also engaging potential partners and investors. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Scancell #CancerResearch #Biotech #Melanoma #ClinicalTrials #Immunotherapy #Pharma #Biotechnology #CancerTreatment #Oncology

American Resources Corp Chief Financial Officer Kirk Taylor joined Steve Darling to announce that its subsidiary, ReElement Technologies Corporation, has secured a $20 million equipment leasing facility with Maxus Capital Group. The financing will support the purchase of large-scale processing equipment aimed at expanding rare earth, battery materials, and critical defense element production across ReElement’s Noblesville and Marion, Indiana facilities. ReElement’s proprietary separation and purification platform is designed to dramatically reduce capital costs, operating expenses, and chemical usage while delivering improved efficiency and scalability. The technology provides a cleaner, lower-cost method of producing ultra-high-purity materials—positioning ReElement as a pioneering midstream supplier in the U.S. critical minerals supply chain. Taylor emphasized that this milestone directly supports U.S. federal objectives, including Presidential executive orders on domestic mineral independence and the Department of Defense’s “mine-to-magnet” initiative, which sets a 2027 goal of establishing a secure, end-to-end domestic supply chain for rare earth magnets. The $20 million facility provides the immediate capital needed to ramp up customer demand at Noblesville, while simultaneously enabling scaled production in Marion—two near-term growth drivers that management expects to significantly increase revenues. With this financing secured, ReElement is strengthening its role as a critical link in the domestic electrification and defense supply chain, positioning itself for long-term growth as demand for sustainable rare earth and battery materials accelerates globally. #proactiveinvestors #americanresourcescorporation #nasdaq #arec #SustainableMining, #MineralRefining, #RecyclingInnovation, #CriticalMinerals, #RareEarthRecycling, #EVRecycling, #BatteryRecycling, #princialminerals #adamjohnson #RareEarths #EWasteRecycling #ReElement #CriticalMinerals #SustainableTech #MagnetRecycling #TechInnovation #GreenSupplyChain #ElectrifiedMaterials